Annexon becomes the latest group to provide a confusing update in the disease.
Lack of clarity on safety and efficacy causes shareholders to decamp.
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.